News: Pharma Mar: TGA Grants "Provisional Approval Pathway" For Lurbinectedin In SCLC In Australia

  1. 184,651 Posts.
    lightbulb Created with Sketch. 2711

    June 3 (Reuters) - Pharma Mar SA PHMR.MC :

    • THERAPEUTIC GOODS ADMINISTRATION (TGA) GRANTS "PROVISIONAL APPROVAL PATHWAY" FOR LURBINECTEDIN IN RELAPSED SMALL CELL LUNG CANCER (SCLC) IN AUSTRALIA
    • THIS DESIGNATION ALLOWS A FASTER APPROVAL OF DRUGS FOR SERIOUS CONDITIONS THAT FILL AN UNMET MEDICAL NEED
    • DATA FROM PHASE II STUDY OF LURBINECTEDIN SHOWED 35% OVERALL RESPONSE RATE IN SECOND-LINE PATIENTS, AND MEDIAN OVERALL SURVIVAL OF 9.3 MONTHS
 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.